Gilead Sciences (GILD) Change in Cash (2009 - 2026)
Gilead Sciences' (GILD) quarterly Change in Cash came in at $65.0 million in Q1 2026, up 103.15% YoY from $32.0 million in Q1 2025, and down 72.1% on a QoQ basis from $233.0 million in Q4 2025.
Gilead Sciences (GILD) Change in Cash (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Change in Cash data on file, last reported at $65.0 million in Q1 2026.
- Quarterly Change in Cash rose 103.15% year-over-year to $65.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$298.0 million (down 109.29% YoY) and the FY2025 annual result came in at -$2.4 billion, down 162.16% from the prior year.
- Change in Cash declined to $65.0 million in Q1 2026, from $233.0 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $5.0 billion in Q4 2024 to a low of -$2.8 billion in Q2 2025.
- A 5-year average of $134.7 million and a median of $65.0 million in 2026 frame the typical range for Change in Cash.
- The widest YoY moves for Change in Cash: up 226300.0% in 2024, down 353.39% in 2024.
- Tracing GILD's Change in Cash over 5 years: stood at $713.0 million in 2022, then plunged by 46.7% to $380.0 million in 2023, then surged by 1203.95% to $5.0 billion in 2024, then slumped by 95.3% to $233.0 million in 2025, then tumbled by 72.1% to $65.0 million in 2026.
- The last three Change in Cash figures came in at $65.0 million (Q1 2026), $233.0 million (Q4 2025), and $2.2 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -1.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -2.82 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.49 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 739.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.95 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -4.45 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -727.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -14.32 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.45 Bn |
| Mar 31, 2026 | 65.00 Mn |
| Dec 31, 2025 | 233.00 Mn |
| Sep 30, 2025 | 2.19 Bn |
| Jun 30, 2025 | -2.78 Bn |
| Mar 31, 2025 | -2.07 Bn |
| Dec 31, 2024 | 4.96 Bn |
| Sep 30, 2024 | 2.26 Bn |
| Jun 30, 2024 | -1.95 Bn |
| Mar 31, 2024 | -1.37 Bn |
| Dec 31, 2023 | 380.00 Mn |
| Sep 30, 2023 | 1.00 Mn |
| Jun 30, 2023 | 768.00 Mn |
| Mar 31, 2023 | -476.00 Mn |
| Dec 31, 2022 | 713.00 Mn |
| Sep 30, 2022 | -40.00 Mn |
| Jun 30, 2022 | 443.00 Mn |
| Mar 31, 2022 | -1.04 Bn |
| Dec 31, 2021 | 976.00 Mn |
| Sep 30, 2021 | -531.00 Mn |